Clinical trials: Stunted Growth
Growth Disorders, Intrauterine Growth Retardation
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation
- Trial name
- NCT01073605
- Testing
- Genotonorm
- Where
- 31 sites in France
- Volunteers
- 208 people
- Sponsor
- Pfizer
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Obstructive Sleep Apnea, Fetal Growth Restriction
Sleep Apnea and Fetal Growth Restriction
This study aims to evaluate the association between obstructive sleep apnea (OSA) and fetal growth restriction (FGR) and to assess the role of auto-titrated positive airway pressure (aPAP) as antenatal therapy in these patients.
- Conditions
- Obstructive Sleep Apnea, Fetal Growth Restriction, Pregnancy Related
- Trial name
- SAFER (NCT04084990)
- Testing
- S9 VPAP Adapt
- Where
- 3 sites in United States, Israel
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature…
- Trial name
- NCT00125164
- Testing
- rhIGF-1 (mecasermin, Tercica, Inc.)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Ipsen
Growth Disorders
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP).
- Trial name
- NCT05382637
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's National Research Institute
Stunting, Wasting
Complementary Food Supplements for Reducing Childhood Undernutrition
The purpose of this study is to test the impact on child growth of three specially formulated complementary food supplements vs. Plumpy'Doz, a previously tested, commercially available complementary food, and vs.
- Trial name
- NCT01562379
- Testing
- Wheat Soy Blend (WSB++), Chickpea based complementary food supplement, Rice based complementary food supplement
- Where
- Bangladesh
- Volunteers
- 5,449 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Postnatal Growth Disorder
Physiologic Approach to Sodium Supplementation in Premature Infants
Postnatal growth failure occurs in up to 50% of very low birth weight (VLBW, <1500 grams at birth) infants as assessed by discharge weight.
- Trial name
- Salt to Grow (NCT03889197)
- Testing
- Sodium supplementation guided by urine sodium concentration algorithm
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Indiana University
Fetal Growth Retardation
Placental Lesions in Fetal Growth Restrictions
The purpose of this research study is to develop imaging methods to diagnose placental injury in pregnancies diagnosed with fetal growth restriction (FGR).
- Trial name
- NCT04839185
- Testing
- Ferumoxytol infusion, MRI scan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Fetal Growth Retardation, Fetal; Slow Growth
Third Trimester Screening of Fetal Growth Restriction
The aim of this trial is to assess the efficacy of two screening protocols for the detection of fetal growth disorders. In Italy at the moment the screening protocol should not be universal but only on clinical indications.
- Trial name
- RELAIS (NCT05787054)
- Testing
- Third trimester ultrasound
- Where
- Italy
- Volunteers
- 813 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Infant, Small for Gestational Age, Infant, Low Birth Weight
KBTH-GIRHL Healthy Birth Weight Study: A Cross-Section
This study was designed and conducted in an effort to establish a comparison group for the Ghana PrenaBelt Trial (NTC02379728). The Ghana PrenaBelt Trial examined the effect, on birth weight, of a belt-like device to help…
- Conditions
- Infant, Small for Gestational Age, Infant, Low Birth Weight, Pregnancy, Sleep
- Trial name
- KBTH-HBWS (NCT03062228)
- Where
- Ghana
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- IWK Health Centre
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals